Clinical Trial Update: A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA) [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update evaluating tocilizumab in Chinese participants with systemic juvenile idiopathic arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Juvenile Idiopathic Arthritis

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Juvenile Idiopathic Arthritis | Phase 4 | Status: COMPLETED